▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1160 by analyst upside · 2026-09-28
ODTX
Odyssey Therapeutics, Inc.
Healthcare · Market Cap $986M · P/E 0x
ANALYST PRICE TARGET
+74.3%
implied upside to consensus target
Current Price $20.51
Consensus Target $35.75
Bull Target $44.0
Bear Target $29.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
3
Hold
0
Sell
0
52-Week Low $15.1
52-Week High $29.05
YTD Return +24.9%
FUNDAMENTALS
Market Cap $986M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.34
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $15.1
52-Week High $29.05
Current Price $20.51
Bear Target $29.0
Bull Target $44.0
● Now $20.51 ● Target $35.75
TRADING DATA
Avg Volume 277K
YTD Return +24.9%
Analyst Count 4
Consensus Buy
Upside to Target +74.3%
Last Updated 2026-09-28

ANALYST SUMMARY

Odyssey Therapeutics, Inc. (ODTX) is currently trading at $20.51 with a Wall Street consensus price target of $35.75, implying potential upside of 74.3% over the next 12 months. 4 analysts currently cover ODTX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $44.0, while the most cautious has a target of $29.0.

ODTX operates in the Healthcare sector with a market capitalisation of $986M. The stock is up 24.9% year-to-date and is currently trading near the lower end of its 52-week range of $15.1 – $29.05.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ODTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ● Initiated
Buy 2026-08-27 31% win rate (48 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-08-07 43% win rate (7 calls)
Oppenheimer reit
Outperform → Outperform 2026-06-18 14% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-06-02 40% win rate (10 calls)
TD Cowen ● Initiated
Buy 2026-06-02 Building track record
Wedbush ● Initiated
Outperform 2026-06-02 Building track record
JP Morgan ● Initiated
Overweight 2026-06-02 43% win rate (7 calls)
Oppenheimer ● Initiated
Outperform 2026-06-02 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
12/30
Consensus clarity
15/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →